A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement
Article Abstract:
The anticoagulant, recombinant hirudin (desirudin), appears to be better than low-molecular-weight heparin (enoxaparin) in preventing deep-vein thrombosis after total hip replacement surgery. Deep-vein thrombosis is the formation of blood clots in the legs, and the tested drugs work by slowing the clotting process. A total of 1,587 patients in 31 European medical centers were randomized into the two treatment groups. There were significantly fewer deep-vein clots in the desirudin group, 18.4%, than in those who received enoxaparin, 25.5%. Similar blood loss was experienced by both patient groups.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients
Article Abstract:
Forty milligrams (mg) of enoxaparin every day appears to reduce the risk of thromboembolism in critically ill patients. Because hospital patients are often inactive, they are at risk of blood clots that travel to other parts of the body and cut off the blood supply. This condition is called thromboembolism. Researchers randomly assigned 1,102 hospital patients to take 40 mg of enoxaparin, 20 mg of enoxaparin or a placebo every day for 6 to 14 days. Enoxaparin is a form of low-molecular weight heparin. The risk of thromboembolism was reduced by more than half in those who took 40 mg.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
Article Abstract:
Enoxaparin may be effective in lowering the incidence of thromboembolism after hip replacement surgery. Thromboembolism occurs when a blood clot forms, travels through the bloodstream and cuts off the blood supply to an organ. A total of 262 patients receiving an artificial hip joint were given enoxaparin during their hospitalization and then were randomly allocated to continue the drug or a placebo for one month. At the end of the study, only 18% of those on enoxaparin developed thromboembolism, compared to 39% of those on placebo. Enoxaparin is low-molecular-weight heparin.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy
- Abstracts: Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. part 2
- Abstracts: A randomized trial of open versus closed vaginal vault in the prevention of postoperative morbidity after abdominal hysterectomy
- Abstracts: The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura
- Abstracts: Pharmacotherapy for obesity - do the benefits outweigh the risks? The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs